Relay Positive Interim Data for RLY-2608 for Clinically Meaningful Progression Free Survival

 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D

33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D

Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia

Data support planned initiation of 2L pivotal study in 2025

Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end

https://www.globenewswire.com/news-release/2024/09/09/2942654/0/en/Relay-Therapeutics-Announces-Positive-Interim-Data-for-RLY-2608-Demonstrating-Clinically-Meaningful-Progression-Free-Survival.html